Citations

Showing 10 of 108083 citations.

374: CORONARY ARTERY DISSECTION DUE TO EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Yadav, Sumeet Kumar, Vivek, Vidhyalakshmy, Nandi, Lia, Khan, Syed Anjum , Ali, Syed F. , Sethi, Aman, Jain, Nitesh , Bawaadam, Hasnain , Jain, Shikha

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 173-173

10.1097/01.ccm.0000907224.63423.7c Get It

Pharmacogenomic Study—A Pilot Study of the Effect of Pharmacogenomic Phenotypes on the Adequate Dosing of Verapamil for Migraine Prevention
Chen, Yi‐Chieh , Mandrekar, Jayawant N. , Robertson, Carrie E. , Starling, Amaal J. , Cutrer, F. Michael , Robertson, Carrie E , Chen, Yi-Chieh , Wang, Han , Chiang, Chia‐Chun

Mayo Clinic

No container title available | December 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2365333/v1 Get It

Abstract OBJECTIVE Using individual pharmacogenomic phenotypes to investigate the factors affecting the efficacy and tolerability of verapamil for migraine prevention. BACKGROUND Verapamil has a wide range of dosing in headache disorders without reliable tools to predict the optimal doses for an individual. METHODS This is a retrospective chart review examining adults with existing pharmacogenomic reports at Mayo Clinic who had used verapamil for migraine. Effects of six cytochrome P450 phenotypes on the minimum effective and maximum tolerable verapamil doses for migraine prevention were assessed. RESULTS The mean minimum effective and maximum tolerable doses for the 33 patients in final analysis were 178.2(20–320) mg and 227.9(20–480) mg. A variety of CYP2C9, CYP2D6, and CYP3A5 phenotypes were found, without significant association with the verapamil doses after adjusting for age, sex, body mass index, and smoking status. CONCLUSIONS We demonstrated a wide range of effective and tolerable verapamil doses used for migraine in a cohort with various pharmacogenomic phenotypes.
996: MAXIMIZING THE GOLDEN HOUR IN CRITICALLY ILL PATIENTS: ASSESSMENT GAPS AT THE TIME OF ADMISSION
Brown, Meghan, Lahori, Simmy , Montgomery, Amy , Dong, Yue , Gajic, Ognjen , Niven, Alexander S.

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 491-491

10.1097/01.ccm.0000909712.84143.a5 Get It

319: NONALCOHOLIC FATTY LIVER DISEASE ASSOCIATION WITH INTUBATION AND SEVERITY OF COVID-19
Jagirdhar, Gowthami Sai Kogilathota , Qasba, Rakhtan K. , Patnaik, Harsha, Flumignan, Anna, Rama, Kaanthi , Reddy, Shiva Teja, Bains, Yatinder , DaCosta, Theodore , Qasba, Rakhtan K , Banga, Akshat , Bansal, Vikas , Kashyap, Rahul

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 145-145

10.1097/01.ccm.0000907008.00758.6e Get It

318: NONALCOHOLIC FATTY LIVER DISEASE ASSOCIATION WITH HOSPITAL AND ICU ADMISSION IN COVID-19
Jagirdhar, Gowthami Sai Kogilathota , Qasba, Rakhtan K. , Flumignan, Anna, Rama, Kaanthi , Patnaik, Harsha, Reddy, Shiva Teja, Bains, Yatinder , DaCosta, Theodore , Qasba, Rakhtan K , Banga, Akshat , Bansal, Vikas , Kashyap, Rahul

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 145-145

10.1097/01.ccm.0000907004.45695.50 Get It

314: EXTRACORPOREAL LIVER ASSIST DEVICE FOR ACUTE LIVER INJURY DUE TO LIKELY PARTIAL UREA CYCLE DISORDER
Kommaraju, Kavya, Hoskote, Sumedh S.

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 143-143

10.1097/01.ccm.0000906992.03033.c9 Get It

301: STOP-VIRUS COLLABORATIVE: A QUALITATIVE ANALYSIS TO FORMING A VIRTUAL LANDSCAPE OF PRACTICE
Vu, Linh, Redmond, Sarah , Gajić, Ognjen, Dong, Yue , Gajic, Ognjen , Niven, Alexander S.

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 136-136

10.1097/01.ccm.0000906940.46587.2a Get It

1134. Lenzilumab Treatment in COVID-19 Pneumonia Reduces Circulating Cytokines and Markers of Systemic Inflammation
Chappell, Dale, Kilcoyne, Adrian , Cerasoli, Frank , Lukas, John C., Durrant, Cameron, Temesgen, Zelalem , Polk, Christopher, Cerasoli, Frank, Lukas, John, Polk, Christopher, Baker, Jason V. , Marconi, Vincent C.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.973 Get It

Abstract Background Coronavirus disease 2019 (COVID-19) results from SARS-CoV-2-induced hyperinflammatory immune response, orchestrated by granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF increases interleukin-6 (IL-6) levels, ultimately leading to increased C-reactive protein (CRP). The LIVE-AIR trial demonstrated that lenzilumab, the GM-CSF neutralizing antibody, improved the likelihood of survival without invasive mechanical ventilation (IMV) in hospitalized COVID-19 patients requiring supplemental oxygen but not IMV. This sub-analysis correlated levels of cytokines before and after lenzilumab treatment. Methods LIVE-AIR was a phase 3, randomized, double-blind, placebo-controlled trial (NCT04351152). Patients hospitalized with COVID-19 pneumonia, requiring only supplemental oxygen, were randomized to receive lenzilumab (1800 mg in three equally divided doses of 600 mg, q8h) or placebo IV infusion, in addition to standard of care which included remdesivir and corticosteroids. Blood taken at baseline (BL) and subsequent to treatment through day 10 (D10) were obtained and analyzed by high sensitivity enzyme immunoassay for GM-CSF, IL-6, and CRP. Results Baseline IL-6 levels (Loge-transformed for all cytokines and biomarkers) were linearly correlated with higher baseline GM-CSF levels (slope=0.60, p< 0.001). Baseline CRP levels were linearly correlated with higher baseline IL-6 levels (slope=0.29, p < 0.001). GM-CSF levels decreased with lenzilumab treatment on day 1 (D1) which persisted through D10 (Table). In contrast, GM-CSF increased with placebo treatment. IL-6 levels decreased only with lenzilumab treatment. CRP following lenzilumab or placebo treatment decreased on D1 to similar levels and further decreased on D10 only with lenzilumab treatment. Cytokine Levels Associated with Lenzilumab Treatment Conclusion Lenzilumab decreased GM-CSF as well as downstream cytokines and systemic biomarkers of inflammation during the hyperinflammatory immune response of COVD-19. Disclosures Dale Chappell, MD, MBA, Humanigen, Inc: Employee|Humanigen, Inc: Ownership Interest Adrian Kilcoyne, MD, Humanigen, Inc: Employee Frank Cerasoli, PhD, Humanigen, Inc: Advisor/Consultant John Lukas, PhD, Humanigen, Inc: Advisor/Consultant Cameron Durrant, MD, Humanigen, Inc: Employee|Humanigen, Inc: Ownership Interest Zelalem Temesgen, MD, Gilead: unrestricted educational grant (to the institution)|Humanigen, Inc: Grant/Research Support|Merck: unrestricted educational grant (to the institution)|ViiV: Advisor/Consultant Christopher Polk, MD, Gilead: Advisor/Consultant Jason Baker, MD, Gilead: Grant/Research Support|Humanigen, Inc: Grant/Research Support Vincent Marconi, MD, Gilead: Grant/Research Support.
1140. Outcomes and Complications of Tocilizumab and Baricitinib use in Transplant Patients with COVID-19
Saleh, Omar Abu , Mendoza, Maria A. , Razonable, Raymund R.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.978 Get It

Abstract Background Immunomodulators have been shown to improve the outcomes of patients with severe COVID-19. However, it is not known if tocilizumab or baricitinib use would be beneficial in transplant patients who are already receiving immunomodulating agents. Moreover, augmented immunomodulation may increase risk of opportunistic infection. There are few studies analyzing the outcomes and complications of these medications in this population. Methods This is a detailed review of the medical records of all transplant patients who received tocilizumab or baricitinib for COVID-19 indication at our multi-state transplant center from April 2020 to March 2022. Results A total of 57 transplant patients received tocilizumab (n=48) or baricitinib (n=9) for management of COVID-19. Baseline characteristics are in Table 1. 60% had received at least one dose of COVID-19 vaccine. At diagnosis, all patients were lymphopenic (median 0.4 x109 cells/L) with high CRP (median 76.8mg/L) and elevated IL-6 levels (median 145.5pg/ml.). The majority had reduction in transplant immunosuppression (75%) and received remdesivir (86%) and dexamethasone (90%). Majority were admitted to the ICU (68%), including 40% who required invasive mechanical ventilation (Table 2). Almost a third developed bacterial or fungal superinfection. Bacterial infections include respiratory cultures with Klebsiella spp, MRSA, P. aeruginosa, Enterobacter spp and Stenotrophomonas. Blood cultures were positive for Klebsiella spp, MDR P. aeruginosa, E faecalis. Fungal infections include three patients with Aspergillus spp infections who received antifungals. No statistical difference was seen in mortality between patients with infections and not infections group. No statistical difference was seen between type of transplants for infection or mortality. Mortality at 90 days was 46%. Conclusion Transplant patients who received tocilizumab or baricitinib for severe or critical COVID-19 have poor outcome. This case series found high rates of mortality and opportunistic superinfections after tocilizumab and baricitinib use compared to the current literature. Future directions include a matched case-control study to compare the outcomes in this population. Disclosures Raymund R. Razonable, MD, Gilead: Grant/Research Support|Glaxo Smith Kline: Advisor/Consultant|Novartis: DSMB|Regeneron: Grant/Research Support|Roche: Grant/Research Support.